Stocks · News reference

BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target

Sep 15, 2026, 9:49 AMBenzinga Newsdesk

BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 14, 2026, 12:04 PMBenzinga Newsdesk
Akebia Therapeutics Doses First Patient In Phase 2 Basket Trial Of Ebribafusp In Rare Complement-Mediated Kidney Diseases
Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathyInitial data is expected in 2027
AKBA
BenzingaSep 8, 2026, 3:38 PMBenzinga Newsdesk
WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5
AKBA
BenzingaAug 8, 2026, 12:20 AMBenzinga Newsdesk
Leerink Partners Downgrades Akebia Therapeutics to Market Perform, Announces $1 Price Target
Leerink Partners analyst Roanna Ruiz downgrades Akebia Therapeutics (NASDAQ:AKBA) from Outperform to Market Perform and announces $1 price target.
AKBA